TradeUP Acquisition Corp.

Investors should note that while trading continues under symbol ESLA, the company has an initial compliance period until February 16, 2027, to restore the stock price above $1.00 for ten consecutive days or implement a reverse stock split, otherwise facing potential delisting.

Cash of $146,670 stands against $9.26 million of current liabilities, of which $8.30 million is owed to a related party. R&D spending, almost all of it paid to that related party, fell about 70% year over year.

The cash condition is stated and then disarmed in the same passage: the Merger Financing must be at least $20,000,000 — equity financing of no less than $15.0 million plus no more than $5,000,000 of debt or equity-linked financing — but the filing says UPTD and Estrella will waive that condition and consummate the business combination as long as they can secure any equity financing or alternative equity injection sufficient to meet the $5,000,001 Net Tangible Assets Requirement. The only cash floor a holder can rely on is that net tangible assets test.

The Current Charter's own floor is the binding one: UPTD will not redeem public shares in an amount that would leave it with net tangible assets of less than $5,000,001 either immediately prior to or upon consummation. The $20,000,000 Merger Financing condition sits above that but is expressly waivable — the filing says the parties are actively seeking the financing and will waive the condition and close so long as any equity financing or alternative equity injection satisfies the $5,000,001 test. Equity financing is to be no less than $15.0 million.

The financing condition is conditional on itself: the filing states that as long as the parties can secure any equity financing or alternative equity injection sufficient to satisfy the Net Tangible Assets Requirement at closing, they will waive the $20,000,000 Merger Financing condition and consummate the combination. The stated shape of that financing — no less than $15.0 million of equity excluding equity-linked securities, and no more than $5,000,000 of debt or equity-linked financing — therefore describes an intention rather than a floor.

The Merger Financing condition is written to be abandoned: the filing states the parties will waive the $20,000,000 condition and consummate the combination as long as they can secure any equity financing or alternative equity injection sufficient to satisfy the Net Tangible Assets Requirement at closing, and UPTD says it is still actively seeking that financing. The charter's own floor is the binding constraint — UPTD will not redeem public shares in an amount that would leave net tangible assets below $5,000,001 either immediately before or upon consummation.

What changed: Estrella Immunopharma, Inc. filed an 8-K on August 21, 2026, reporting that Nasdaq notified the company on August 17, 2026, of non-compliance with the $1.00 minimum bid price requirement due to closing prices below that threshold for 30 consecutive business days from July 6 through August 14, 2026. Why it matters: Investors should note that while trading continues under symbol ESLA, the company has an initial compliance period until February 16, 2027, to restore the stock price above $1.00 for ten consecutive days or implement a reverse stock split, otherwise facing potential delisting.

What changed: Q2 2026 10-Q of Estrella Immunopharma, Inc. (Nasdaq: ESLA). Cash and equivalents fell to $146,670 at June 30, 2026 from $1,384,302 at December 31, 2025, and total assets to $1,824,681 from $3,176,975. Total current liabilities fell to $9,256,014 from $13,543,033, principally because the related-party accrued liability fell to $8,304,999 from $12,393,333, while derivative liabilities rose to $687,224 from $356,505. The stockholders' deficit narrowed to $(7,431,333) from $(10,366,058) and the accumulated deficit is $41,589,218. Why it matters: Cash of $146,670 stands against $9.26 million of current liabilities, of which $8.30 million is owed to a related party. R&D spending, almost all of it paid to that related party, fell about 70% year over year.

What changed: Estrella Immunopharma, Inc., successor to TradeUP Acquisition Corp., reported the results of its combined 2025/2026 annual meeting held virtually on June 29, 2026. Of 43,034,228 shares outstanding on the May 20, 2026 record date, holders of 30,351,608 were present or represented, about 70.5%. One proposal was put: stockholders ratified Macias Gini O'Connell LLP as independent registered public accounting firm for the year ending December 31, 2026, with 30,351,203 for, 400 against, 5 abstaining and no broker non-votes. Why it matters: A single-proposal annual meeting ratifying an auditor changes nothing about the company's obligations or capital. It is recorded for the governance history and as confirmation of who audits the accounts.

What changed: Estrella Immunopharma, Inc., successor to TradeUP Acquisition Corp., called a combined 2025/2026 annual meeting for June 29, 2026 at 10:00 a.m. ET, record date May 20, 2026, with 43,034,228 shares outstanding on the record date. Business is limited to ratifying the independent registered public accounting firm for the year ending December 31, 2026 and any other properly brought business; a quorum requires a majority in voting power of outstanding shares. A stockholder list is available for examination from June 19, 2026. Why it matters: No trust, deadline or redemption right remains for UPTD holders. Combining the 2025 and 2026 annual meetings into one mid-2026 event means the company skipped an annual meeting cycle, which is usually a cost and bandwidth signal at a small-cap issuer rather than a governance dispute. The 43,034,228 share count is the base against which any future financing dilution should be measured.